Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2022 08:01 ET | Source: Salarius Pharmaceuticals, Inc.

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS) and chronic...
December 13, 2022 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®) Synergistic activity with rituximab in DLBCL...
December 08, 2022 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
December 01, 2022 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing...
November 10, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
November 03, 2022 09:57 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
October 27, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of...
October 19, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
October 18, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
October 14, 2022 08:43 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right